JPWO2022140586A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022140586A5 JPWO2022140586A5 JP2023537689A JP2023537689A JPWO2022140586A5 JP WO2022140586 A5 JPWO2022140586 A5 JP WO2022140586A5 JP 2023537689 A JP2023537689 A JP 2023537689A JP 2023537689 A JP2023537689 A JP 2023537689A JP WO2022140586 A5 JPWO2022140586 A5 JP WO2022140586A5
- Authority
- JP
- Japan
- Prior art keywords
- chr6
- hla
- cell
- engineered
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130095P | 2020-12-23 | 2020-12-23 | |
| US63/130,095 | 2020-12-23 | ||
| US202163250996P | 2021-09-30 | 2021-09-30 | |
| US63/250,996 | 2021-09-30 | ||
| US202163254970P | 2021-10-12 | 2021-10-12 | |
| US63/254,970 | 2021-10-12 | ||
| US202163288492P | 2021-12-10 | 2021-12-10 | |
| US63/288,492 | 2021-12-10 | ||
| PCT/US2021/064930 WO2022140586A2 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for reducing hla-a in a cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500858A JP2024500858A (ja) | 2024-01-10 |
| JPWO2022140586A5 true JPWO2022140586A5 (https=) | 2025-07-08 |
| JP2024500858A5 JP2024500858A5 (https=) | 2025-07-08 |
Family
ID=81212453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537689A Pending JP2024500858A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｈｌａ－ａを低減するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024478A1 (https=) |
| EP (1) | EP4267724A2 (https=) |
| JP (1) | JP2024500858A (https=) |
| KR (1) | KR20230124664A (https=) |
| AU (1) | AU2021409732A1 (https=) |
| CA (1) | CA3206284A1 (https=) |
| CL (2) | CL2023001860A1 (https=) |
| CO (1) | CO2023009612A2 (https=) |
| CR (1) | CR20230320A (https=) |
| IL (1) | IL303971A (https=) |
| MX (1) | MX2023007466A (https=) |
| TW (1) | TW202239959A (https=) |
| WO (1) | WO2022140586A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3228879A1 (en) * | 2021-08-16 | 2023-02-23 | Beam Therapeutics Inc. | Persistent allogeneic modified immune cells and methods of use thereof |
| EP4599046A1 (en) * | 2022-10-05 | 2025-08-13 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| AU2024324870A1 (en) | 2023-08-14 | 2026-02-12 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202521564A (zh) | 2023-08-14 | 2025-06-01 | 美商英特利亞醫療公司 | 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3134515B1 (en) * | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| AU2017374044B2 (en) | 2016-12-08 | 2023-11-30 | Intellia Therapeutics, Inc. | Modified guide RNAs |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| EP3754018A4 (en) * | 2018-02-16 | 2021-11-24 | Kyoto University | LOW ANTIGENIC CELL PRODUCTION PROCESS |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| WO2019237069A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| BR112021007123A2 (pt) | 2018-10-15 | 2021-08-10 | University Of Massachusetts | edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase |
| JP2022512703A (ja) | 2018-10-16 | 2022-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のための組成物および方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| GB2596660B (en) * | 2019-01-07 | 2023-09-13 | Crisp Hr Therapeutics Inc | A non-toxic Cas9 enzyme and application thereof |
| KR20230017783A (ko) * | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
-
2021
- 2021-12-22 AU AU2021409732A patent/AU2021409732A1/en active Pending
- 2021-12-22 IL IL303971A patent/IL303971A/en unknown
- 2021-12-22 TW TW110148217A patent/TW202239959A/zh unknown
- 2021-12-22 EP EP21856911.9A patent/EP4267724A2/en active Pending
- 2021-12-22 CR CR20230320A patent/CR20230320A/es unknown
- 2021-12-22 CA CA3206284A patent/CA3206284A1/en active Pending
- 2021-12-22 MX MX2023007466A patent/MX2023007466A/es unknown
- 2021-12-22 KR KR1020237024853A patent/KR20230124664A/ko active Pending
- 2021-12-22 WO PCT/US2021/064930 patent/WO2022140586A2/en not_active Ceased
- 2021-12-22 JP JP2023537689A patent/JP2024500858A/ja active Pending
-
2023
- 2023-06-20 CL CL2023001860A patent/CL2023001860A1/es unknown
- 2023-06-22 US US18/339,665 patent/US20240024478A1/en active Pending
- 2023-07-19 CO CONC2023/0009612A patent/CO2023009612A2/es unknown
- 2023-10-17 CL CL2023003086A patent/CL2023003086A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240309373A1 (en) | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | |
| JP7101419B2 (ja) | 内因性ｔ細胞受容体の標的置換 | |
| US20240252543A1 (en) | Crispr/cas-related methods and compositions for improving transplantation | |
| JP2022512703A (ja) | 免疫療法のための組成物および方法 | |
| CN115103910A (zh) | 具有工程化的双引导核酸的crispr系统 | |
| JPWO2022140586A5 (https=) | ||
| WO2022093846A1 (en) | Safe harbor loci | |
| JP2024506016A (ja) | 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法 | |
| JPWO2022256440A5 (https=) | ||
| KR102264115B1 (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| US20240307444A1 (en) | Methods and compositions for improved immunotherapies | |
| CN120129746A (zh) | 用于减少细胞中的mhc i类的组合物和方法 | |
| JPWO2022140587A5 (https=) | ||
| JP2024505678A (ja) | 免疫療法のためのリンパ球活性化遺伝子３（ｌａｇ３）組成物及び方法 | |
| KR20180018466A (ko) | 면역세포의 면역조절 유전자의 활성 조절을 위한 조성물 및 그 용도 | |
| US20230383252A1 (en) | Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy | |
| WO2020103013A1 (en) | Modified t cells and uses thereof | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| RU2025100294A (ru) | Композиции и способы снижения содержания mhc класса i в клетке | |
| KR102213837B1 (ko) | 유전자가 조작된 nk 세포 및 이의 이용방법 | |
| US20250276017A1 (en) | Compositions and Methods for Genomic Editing | |
| Babu et al. | Cancer gene therapies progress in pre and postgenomics era | |
| TW202542303A (zh) | 經工程改造之ｔ細胞 | |
| WO2026085201A2 (en) | Base editing to correct inborn errors of immunity | |
| WO2026019837A1 (en) | Compositions and methods for overcoming t-cell exhaustion |